Chemomab Therapeutics Ltd. Sponsored ADR CMMB 深 沪
已收盘 02-06 16:00:00 美东时间
1.5303
+0.080
+5.54%
华盛通- 最 高1.55
- 今 开1.50
- 成交量 3.32万股
- 最 低 1.50
- 昨 收 1.45
- 总市值 941.92万
- 52周最高 8.24
- 市盈率 静 --
- 换手率 0.54%
- 52周最低 1.42
- 委 比 50.00%
- 总股本 615.51万
- 历史最高 736.00
- 量 比 0.51
- 振 幅 3.45%
- 历史最低 1.42
- 每 手 1
- 风险率 1.56%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Chemomab Therapeutics Data From Phase 2 SPRING Study Shows Nebokitug Was Safe, Well Tolerated In Participants With Primary Sclerosing Cholangitis At Up To 48 Weeks Of Treatment
Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the results of
2025-12-02 21:16
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
Chemomab Therapeutics Ltd. announced that its co-founder and CEO, Dr. Adi Mor, will present at Oppenheimer's Movers in Rare Disease Summit on December 11, 2025, in New York City. Dr. Mor will provide a corporate overview and hold one-on-one meetings with attendees. Chemomab is a biotech company developing innovative therapeutics for fibro-inflammatory diseases, particularly focusing on nebokitug, a first-in-class monoclonal antibody targeting CCL...
2025-11-24 13:00
Chemomab Therapeutics Advances PSC Treatment with Phase 3 Trial
Chemomab Therapeutics Ltd. ( ($CMMB) ) has released its Q3 earnings. Here is a ...
2025-11-22 11:53
Chemomab Therapeutics GAAP EPS of $0.00
Chemomab Therapeutics press release (CMMB): Q3 GAAP EPS of $0.00. Net loss was $1.7 million, or a net loss of less than one-half of one cent per basic and diluted ordinary share for the third quarter ...
2025-11-20 21:33
Chemomab Therapeutics Q3 EPS $(0.28) Beats $(0.40) Estimate
Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.40) by 30 percent. This is a 65 percent increase over losses of $(0.80) per share from
2025-11-20 21:30
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Chemomab Therapeutics Ltd announced positive updates on its nebokitug Phase 3 trial design for primary sclerosing cholangitis (PSC), receiving support from both the FDA and EMA for a single registration trial using a clinical event composite endpoint. Data from the Phase 2 SPRING trial's open-label extension (OLE) showed favorable safety and consistent improvements in key biomarkers, further reinforcing nebokitug's disease-modifying potential. Th...
2025-11-20 13:00
Chemomab To Present Abstracts Highlighting New Clinical Data From Nebokitug Phase 2 SPRING Trial In Primary Sclerosing Cholangitis, At AASLD 2025
— Phase 2 SPRING Trial Open Label Extension Showed Favorable Safety and Consistent Improvements in Key Biomarkers in PSC Patients Treated with Nebokitug for Up to 48 Weeks——New Clinical Data Provides Insights on
2025-11-06 21:09
Chemomab Therapeutics Advances Phase 3 Plans for Nebokitug
Chemomab Therapeutics Ltd. ( ($CMMB) ) has released its Q2 earnings. Here is a ...
2025-09-13 11:50
美股大行评级 | 最高至425美元！MONGODB获多家机构上调目标价；德银上调回声星通信(SATS)目标价升至67美元
今日重点评级关注：Oppenheimer：维持Chemomab Therapeutics"跑赢大市"评级，目标价从10美元升至25美元；花旗：维持MongoDB"买入"评级，目标价从405美元升至425美元
2025-08-28 09:51
Oppenheimer Maintains Outperform on Chemomab Therapeutics, Raises Price Target to $25
Oppenheimer analyst Jeff Jones maintains Chemomab Therapeutics (NASDAQ:CMMB) with a Outperform and raises the price target from $10 to $25.
2025-08-28 00:22
